The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 553-558

  Mohamed, Randa H ^a   Mohamed, Rasha H ^b   Karam, Rehab A ^a   Abd El Aziz, Tarek A ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

CAD; Lipoprotein oxidation susceptibility; PON1 activity; PON1 polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; NITRATE;

ADULT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; EGYPT; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE ACTIVITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; EGYPT; ENZYME ACTIVATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 77950859888     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.015     Document Type: Article

References (43)

1. Carew T.E. Role of biologically modified low-density lipoprotein in atherosclerosis. Am. J. Cardiol. 1989, 64:18G-22G.
2. Sen-Banerjee S., Siles X., Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2120-2126.
3. Turban S., Fuentes F., Ferlic L., et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and resPON1se to fluvastatin. Atherosclerosis 2001, 154:633-640.
4. Granér M., James R.W., Kahri J., Nieminen M.S., Syvänne M., Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J. Am. Coll. Cardiol. 2006, 47:2429-2435.
5. Hong S.H., Songb J., Minc W.K., Kimb J.Q. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin. Biochem. 2001, 34:475-481.
6. Pfohl M., Koch M., Euderle M.D., et al. Paraoxonase 192 Glu/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999, 48:623-627.
7. Primo-Parmo S.L., Sorenson R.C., Teiber J., LaDu B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
8. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 1996, 7:69-76.
9. Suehiro T., Nakauchi Y., Yamamoto M., et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 1996, 57:69-73.
10. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1067-1173.
11. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 1995, 15:89-95.
12. Boright A.P., Connelly P.W., Brunt J.H., Scherer S.W., Tsui L.C., Hegele R.A. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma in Alberta Hutterites. Atherosclerosis 1998, 139:131-136.
13. Frieldewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
14. Dujovne C.A., Harris W.S., Colle Gerrond L.L., Fan J., Muzio F. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am. J. Cardiol. 1994, 74:38-42.
15. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-198.
16. Chen Q., Reis S.E., Kammerer C.M., McNamara D.M., Holubkov R., Sharaf B.L. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 2003, 72:13-22.
17. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1617-1624.
18. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
19. Imai Y., Marita H., Kurihara H., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149:435-442.
20. Aubó C., Sentí M., Marragut J., et al. Risk of myocardial infarction with Gln/Arg 192 polymorphisms in the human paraoxonase gene and diabetes mellitus. Eur. Heart J. 2000, 21:31-38.
21. Hasselwander O., Savage D.A., McMaster D., et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 1999, 56:289-298.
22. De Rijke Y.B., Verwey H.F., Vogelezang C.J., Van Der Velde E.A., Princen H.M., Van Der Laarse A. Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atheroscerosis. Clin. Chim. Acta. 1995, 243:137-149.
23. Regnström J., Nilsson J., Tornvall P., Landou C., Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992, 339:1183-1186.
24. Croft K.D., Dimmitt S.B., Moulton C., Beilin L.J. Low density lipoprotein composition and oxidizability in coronary disease-apparent favourable effect of beta blockers. Atherosclerosis 1992, 97:123-130.
25. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Hill E. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1451-1457.
26. Azarsi{dotless}za E., Kayi{dotless}kci{dotless}o, lub M., Payzi{dotless}nb S., Sözmen E.Y. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int. J. Cardiol. 2003, 91:43-51.
27. Ruiz J., Blanche' H., James R.W., et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
28. Herrmann S.M., Blanc H., Poirier O., et al. The Gln/Arg polymorphism of human paraoxonase (PON1 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996, 126:299-303.
29. Rice G.I., Ossei-Gerning N., Stickland M.H., Grant P.J. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 1997, 8:677-682.
30. Cao H., Girard-Globa A., Berthezene F., Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism. J. Lipid Res. 1999, 40:133-139.
31. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998, 423:57-60.
32. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 1999, 26:892-904.
33. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPON1A) gene is a risk factor for coronary artery disease. J. Clin. Invest 1995, 96:3005-3008.
34. Ko Y.L., Ko Y.S., Wang S.M., et al. The Gln-Arg191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998, 141:259-264.
35. Zama T., Murata M., Matsubara Y., et al. A 192Arg variant of the human paraoxonase (HUMPON1A) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 1997, 17:3565-3569.
36. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192Arg) is associated with coronary artery disease in Japanese non insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82:2257-2260.
37. Humbert R., Adler D.A., Disteche C.K., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3:73-76.
38. Adkins S., Gan K.N., Mody M., LaDu B.N. Molecular basis for the polymorphic forms of human serum paraoxonase: arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 52:598-608.
39. Mackness M.I., Arrol S., Mackness B., Durrington P.N. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997, 349:851-852.
40. Mackness M.I., Durrington P.N., Mackness B. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid oxidation. Lancet 1999, 353:468-469.
41. Regieli J.J., Jukema J.W., Doevendans P.A., Zwinderman A.H., Kastelein J.J., Grobbee D.E., Graaf Y.V. Paraoxonase variants relate to 10-year risk in coronary artery disease impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol. 2009, 54:1238-1245.
42. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step I. J. Lipid Res. 2000, 41:1481-1494.
43. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139:307-315.